Overview

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)

Status:
Completed

Trial end date:
2019-04-24

Target enrollment:

Participant gender:

Summary

This Phase III study was designed to evaluate the efficacy and safety of KX2-391 Ointment 1% in adult participants when applied to an area of skin containing 4-8 stable, clinically typical actinic keratosis (AK) lesions on the face or scalp.

Phase:

Phase 3

Details

Lead Sponsor:

Almirall, S.A.
Athenex, Inc.

Collaborator:

Athenex, Inc.

Treatments:

Tirbanibulin